Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases. Despite advances in targeted therapies and immune checkpoint inhibitors, many patients experience disease progression, highlighting the need for novel therapeutic approaches.  JY-DC001 is our autologous dendritic cell-based therapy, initially developed for the treatment of lung cancer. The goal is to stimulate a strong and durable anti-tumor immune response by enhancing antigen presentation and T cell activation. This therapy is designed to complement existing treatment modalities and improve clinical outcomes for patients with advanced lung cancer.  We are advancing JY-DC001 through preclinical and early clinical development, evaluating its safety, immunogenicity, and therapeutic potential.